Wednesday 7 March 2018

Contents

- PrEP use growing in US, but not reaching all those in need
- New HIV infections halved after scale-up of HIV treatment and circumcision
- Bictegravir-based combination maintains viral suppression after switching therapy
- Success of same-day start to HIV treatment in Lesotho
- Twice-daily dolutegravir and TB treatment
- New resources: Living with HIV as you get older
- Support our work

PrEP use growing in US, but not reaching all those in need

Graphic from the AIDSVu website: https://aidsvu.org/resources/mapping-prep

The number of people taking HIV pre-exposure prophylaxis (PrEP) in the United States is steadily increasing, but PrEP is only reaching a small proportion of those who could benefit from it. The 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) in Boston was told this week. Although African Americans and Latinos make up about two-thirds of people who stand to benefit from PrEP, they are much less likely than white people to be using it.

For several years, Gilead Sciences, the maker of Truvada, has been reporting PrEP use estimates based on surveys of commercial pharmacies (thought to represent over 85% of PrEP
prescriptions). Gilead have now collaborated with Patrick Sullivan of Emory University and AIDSVu to present the data. This could help health departments, medical professionals and community leaders to better understand and reduce disparities in PrEP usage.

Data come from 54,000 commercial pharmacies and a number of other medical settings, and include prescriptions paid by Medicaid and patient assistance programmes. However, it does not include demonstration studies, military veterans’ health systems and managed care providers that run their own pharmacies, such as Kaiser Permanente.

During 2016, 77,120 people were using PrEP, up from 8768 in 2012. But behind these overall numbers lie some notable demographic and geographic disparities.

Although women account for about 19% of all new HIV diagnoses in the US, they make up only 7% of PrEP users. While 21% of new diagnoses are in people under the age of 25, only 11% of PrEP users are in this age group.

More than half of all new HIV diagnoses occur in the south, but this region was home to only 30% of PrEP users. After adjusting for population size, the states of New York, Massachusetts, Rhode Island, Washington and Illinois had the highest PrEP usage rates.

States with a higher proportion of people living in poverty, more people without health insurance and those that did not implement Medicaid expansion under President Obama’s health reforms have lower rates of PrEP usage.

Prescription data often do not include information about race, but the Centers for Disease Control and Prevention (CDC) estimate that only 1% of African Americans who meet the PrEP eligibility criteria are using PrEP. Similarly, only 3% of Latinos are using PrEP.

There was a smaller but still considerable gap for white people, with 14% of eligible individuals receiving PrEP.

Related links

- Read this news story in full on aidsmap.com
- Watch the webcast on the conference website
- Visit the CROI 2018 webpages on aidsmap.com

New HIV infections halved after scale-up of HIV treatment and circumcision

The rate of new HIV infections has halved since 2011 in a hyperendemic Ugandan fishing community following large increases in male circumcision, antiretroviral treatment and viral suppression, the conference was told on Tuesday.

The study was based on repeat surveys in a single fishing community with a very high incidence and prevalence of HIV. Located on the shore of Lake Victoria, this is one of the communities that participates in the Rakai Community Cohort. Surveys were conducted with a total of 5005 people aged between 15 and 49 years, between 2011 and 2017.

During this time:

- The proportion of people with HIV taking antiretroviral treatment increased from 19% to 81%.
The proportion of people with HIV (including undiagnosed people) who were virally suppressed rose from 33% to 78%.

The proportion of men who were circumcised rose from 39% to 63%.

There was no change in sexual behaviour.

Following this, overall HIV incidence more than halved from 3.97 per 100 person-years in 2011 to 1.61 per 100 person-years in 2017, a 58% reduction. Similar declines in incidence occurred in women and in men. Substantial falls were seen in all age groups, but especially in people aged 15 to 24 years.

HIV prevalence fell from 41% to 36%.

Dr Joseph Kagaayi of the Rakai Health Sciences Program said that his findings are amongst the first to show that combination HIV prevention can successfully reduce HIV incidence in a hyperendemic community. “These results suggest that HIV treatment and prevention interventions can be rapidly scaled and have substantial population-level impact on HIV incidence in high prevalence settings,” he commented.

Related links

Read this news story in full on aidsmap.com
Watch the webcast on the conference website

Bictegravir-based combination maintains viral suppression after switching therapy

People who switched to a single-tablet regimen containing the integrase inhibitor bictegravir were as likely to maintain an undetectable viral load as those who stayed on their current suppressive regimen containing dolutegravir, according to a presentation at CROI 2018.

Gilead Science’s bictegravir is a next-generation integrase strand transfer inhibitor. In February, US regulators approved Biktarvy, a new once-daily single tablet regimen containing bictegravir, emtricitabine and tenofovir alafenamide (TAF), the new kidney- and bone-friendly formulation of tenofovir. The combination pill is currently under regulatory review in Europe.
Previous studies, in people taking HIV treatment for the first time, have shown that the bictegravir combination was non-inferior to regimens containing ViiV Healthcare’s integrase inhibitor dolutegravir.

The study presented this week evaluated the bictegravir combination in people changing treatment. Eligible patients already had suppressed viral load on a regimen containing dolutegravir, lamivudine and abacavir (the drugs in the Triumeq single-tablet regimen).

A total of 563 participants were recruited in Europe, North American and Australia. They were predominantly male and white, with a CD4 cell count of around 700 cells/mm$^3$. The study only recruited participants with moderate or better kidney function (estimated glomerular filtration rate or eGFR above 50 ml/min).

At 48 weeks, viral suppression rates were high in both arms: 98.6% in the bictegravir group and 95.0% in the dolutegravir group. No participants developed treatment-emergent resistance to any study drug.

Both treatment regimens were generally safe and well tolerated. Half as many people in the bictegravir group experienced drug-related adverse events (mostly headache), but eGFR rose by a small amount in the bictegravir group while falling slightly in the dolutegravir group.

The researchers concluded that switching to bictegravir was non-inferior to continuing on a dolutegravir-based regimen in terms of efficacy and safety.

When asked what might motivate someone who is doing well on dolutegravir to switch to Biktarvy, they noted that the tenofovir-containing regimen might be preferable for someone with hepatitis B co-infection, as tenofovir is active against both HIV and hepatitis B.

Related links

Read this news story in full on aidsmap.com

Watch the webcast on the conference website

Success of same-day start to HIV treatment in Lesotho
Starting treatment at home, on the day of diagnosis, proved acceptable in rural Lesotho and resulted in improved linkage to care and viral suppression compared with routine care, the conference was told.

A number of studies in sub-Saharan African countries have reported substantial problems with linkage to care following diagnosis. Home-based testing programmes have found that only one in three people diagnosed with HIV link to care if they receive a referral — more active measures are needed.

The CASCADE study was carried out in a mountainous district of Lesotho where around half of people need to walk to a clinic. Individuals who had been diagnosed with HIV during a home-based testing and counselling campaign were randomised to either receive a 30-day supply of antiretroviral drugs on the day of diagnosis or the standard of care (referral to a medical facility for antiretroviral therapy [ART]).

Of 441 adults who were diagnosed as part of the campaign, 278 were willing and eligible to participate. Those taking part needed to agree that they understood the implications of starting lifelong ART after home-based counselling.

Same-day initiation resulted in significantly greater proportions linked to care within three months (68.6% in the same-day arm and 43.1% in the standard-of-care arm). It also resulted in a significantly greater proportion being virally suppressed after 12 months (50.4% in the same-day arm and 34.3% in the standard-of-care arm).

Around 30% in each arm did not link to care because they were ‘too busy’; 25% in the same-day-initiation arm and 30% in the standard-of-care arm were lost to follow-up; and 10% said they did not understand that they should have attended care when traced by a community health worker.

Dr Niklaus Labhardt of the Swiss Public Health Institute said that the results were likely to be generalisable to other rural settings in sub-Saharan Africa where home-based testing and counselling is being implemented.

Related links

- Read this news story in full on aidsmap.com
- Watch the webcast on the conference website

Twice-daily dolutegravir and TB treatment
Twice-daily dosing of dolutegravir when combined with the tuberculosis (TB) drug rifampicin is safe and effective, according to a 24-week interim analysis of the INSPIRING study. The results suggest that dolutegravir can be used alongside TB treatment as part of first-line antiretroviral treatment.

Dolutegravir is recommended as an alternative to efavirenz in first-line antiretroviral treatment in lower- and middle-income countries and a fixed-dose combination pill containing dolutegravir, tenofovir and lamivudine priced at $75 a year became available in 2017. Although dolutegravir has relatively few drug interactions with other medicines, a pharmacokinetic study showed that rifampicin reduces dolutegravir blood levels.

When dolutegravir received marketing approval regulators recommended that the drug should be dosed twice daily if used alongside rifampicin to overcome the drug interaction. The INSPIRING study was designed to provide evidence that this dosing pattern is safe and effective.

The phase 3a, randomised, open-label study recruited 113 participants, all of whom had been taking rifampicin-based TB therapy for at least eight weeks and had a CD4 cell count above 50 cells/mm$^3$. The participants were randomised to receive an antiretroviral therapy regimen based on either twice-daily dolutegravir or once-daily efavirenz. A minimum of two weeks after completing TB treatment, those in the dolutegravir arm could switch to once-daily dosing.

At baseline, the median CD4 cell count in both arms was a little over 200 cells/mm$^3$. The viral load in both arms was around $5 \log_{10}$ copies/ml.

After 24 weeks, viral load was undetectable in 81% of people in the dolutegravir arm and 89% of the efavirenz arm. This difference appeared to be driven by more discontinuations unrelated to therapy in the dolutegravir arm.

CD4 cell increases were comparable between the two regimens (146 cells/mm$^3$ for dolutegravir vs 93 cells/mm$^3$ for efavirenz).

Only two people, both of whom were in the efavirenz arm, stopped treatment because of side-effects. There were no discontinuations due to liver-related side-effects. The rate of immune reconstitution inflammatory syndrome (IRIS) was low (6% for dolutegravir vs 9% for efavirenz).

The study is continuing, but the investigators believe that these interim results support the use of dolutegravir-based regimens in HIV/TB co-infection.
New resources: Living with HIV as you get older

A range of resources on health problems, co-morbidities and challenges that people living with HIV may face as they get older is available online.

This includes factsheets, an online Side-effects checker tool, Side-effects information booklet and translated editions of a number of our factsheets in Spanish, Portuguese and Greek.
This message from one of our supporters made us smile! As a charity we rely on donations to continue our work and are so grateful for every gift we receive, no matter how big or small.

We believe passionately that independent, clear and evidence-based information lies at the heart of empowering people to make decisions about their health and live longer, healthier, happier lives.

If you can feel you can support our work with a donation, you can do so online at www.aidsmap.com/donate.

Thank you.

Related links

www.aidsmap.com/donate

Connect with NAM on Facebook: Keep up to date with all the exciting projects, latest achievements and new developments that are going on in the world of NAM.

Follow NAM on twitter for links to hot off the press news stories from our editors covering key developments and conferences as they happen. Our news feed is linked to www.twitter.com/aidsmap_news and we also tweet from www.twitter.com/aidsmap.

Follow all the conference news by subscribing to our RSS feeds.

NAM's news coverage of the 2018 Conference on Retroviruses and Opportunistic Infections has
been supported by a grant from Gilead Sciences Europe Ltd.

NAM is an award-winning, community-based organisation, which works from the UK. We deliver reliable and accurate HIV information across the world to HIV-positive people and to the professionals who treat, support and care for them.

Make a donation, make a difference at www.aidsmap.com/donate

For more details, please contact NAM:
tel: +44 (0)20 7837 6988
fax: +44 (0)20 7923 5949
email: info@nam.org.uk
web: www.aidsmap.com

NAM Publications
Registered office: Acorn House, 314-320 Gray’s Inn Road, London, WC1X 8DP
Company limited by guarantee. Registered in England & Wales, number: 2707596
Registered charity, number: 1011220

To unsubscribe please visit: http://www.aidsmap.com/page/1492854/

Privacy Policy
Read it here: http://www.aidsmap.com/page/1439297/